TEVA Q2 2021 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B+1.0% YoY

Gross Profit

$1.9B47.9% margin

Operating Income

$582M14.9% margin

Net Income

$207M5.3% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

$218M

Free Cash Flow

$105M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$49.2B

Total Liabilities

$37.9B

Stockholders' Equity

$10.3B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$3.9B	+1.0%
Gross Profit	$1.9B	$1.8B	+6.2%
Operating Income	$582M	$173M	+236.4%
Net Income	$207M	$140M	+47.9%

Revenue Segments

Product

$3.5B89%

Distribution Service

$330M8%

Product and Service, Other

$96M2%

License

$19M0%

Geographic Segments

North America Segment

$1.9B54%

Europe Segment

$1.2B33%

International Markets

$485M13%